YU83502A - Nova farmaceutska smeša - Google Patents
Nova farmaceutska smešaInfo
- Publication number
- YU83502A YU83502A YU83502A YUP83502A YU83502A YU 83502 A YU83502 A YU 83502A YU 83502 A YU83502 A YU 83502A YU P83502 A YUP83502 A YU P83502A YU 83502 A YU83502 A YU 83502A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- pharmaceutical composition
- new pharmaceutical
- pharmaceutically acceptable
- composition
- erythropoiesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Abstract
Ovaj pronalazak se odnosi na tečnu farmaceutsku smešu koja se sastoji od eritropoetinskog proteina, višestruko naelektrisanog neorganskog anjona u farmaceutski prihvatljivom puferu koji je pogodan da održava pH rastvora u opsegu od oko 5,5 do oko 7,0 i opciono jednog ili više farmaceutski prihvatljivih ekscipijenata (inertnih punila). Ova smeša je naročito prikladna za profilaksu i terapiju bolesti koje su u vezi sa eritropoezom.[The present invention relates to a liquid pharmaceutical composition comprising an erythropoietin protein, a multiple charged inorganic anion in a pharmaceutically acceptable buffer suitable to keep the solution pH in the range from about 5.5 to about 7.0, and optionally one or more pharmaceutically acceptable excipients. This composition is especially useful for the prophylaxis and treatment of diseases related to erythropoiesis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00110355 | 2000-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
YU83502A true YU83502A (sh) | 2005-11-28 |
RS51292B RS51292B (sr) | 2010-12-31 |
Family
ID=8168722
Country Status (36)
Country | Link |
---|---|
US (2) | US7169754B2 (sh) |
EP (2) | EP1525889A1 (sh) |
JP (1) | JP3967594B2 (sh) |
KR (3) | KR20070032815A (sh) |
CN (1) | CN1309416C (sh) |
AR (2) | AR035034A1 (sh) |
AT (1) | ATE291436T2 (sh) |
AU (1) | AU784091B2 (sh) |
BR (1) | BRPI0110914B8 (sh) |
CA (1) | CA2408685C (sh) |
CZ (1) | CZ304855B6 (sh) |
DE (1) | DE60109625T3 (sh) |
DK (1) | DK1311285T4 (sh) |
EC (2) | ECSP024352A (sh) |
ES (1) | ES2237574T5 (sh) |
HK (1) | HK1056683A1 (sh) |
HR (1) | HRP20020880B1 (sh) |
HU (1) | HU230874B1 (sh) |
IL (2) | IL152659A0 (sh) |
JO (1) | JO3404B1 (sh) |
MA (1) | MA26901A1 (sh) |
ME (1) | MEP90708A (sh) |
MX (1) | MXPA02011303A (sh) |
MY (1) | MY128654A (sh) |
NO (1) | NO330934B1 (sh) |
NZ (1) | NZ522030A (sh) |
PE (1) | PE20020050A1 (sh) |
PL (1) | PL219131B1 (sh) |
PT (1) | PT1311285E (sh) |
RS (1) | RS51292B (sh) |
RU (1) | RU2281116C2 (sh) |
SI (1) | SI1311285T1 (sh) |
TW (2) | TWI288643B (sh) |
UY (1) | UY26704A1 (sh) |
WO (1) | WO2001087329A1 (sh) |
ZA (1) | ZA200208500B (sh) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US5545553A (en) * | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
US7304150B1 (en) * | 1998-10-23 | 2007-12-04 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
CA2405709A1 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2001087329A1 (en) | 2000-05-15 | 2001-11-22 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivate |
ATE505204T1 (de) * | 2000-12-20 | 2011-04-15 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
MXPA03005406A (es) * | 2000-12-20 | 2003-09-25 | Hoffmann La Roche | Conjugados de eritropoyetina. |
FR2823220B1 (fr) * | 2001-04-04 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo) |
US20030143191A1 (en) * | 2001-05-25 | 2003-07-31 | Adam Bell | Chemokine beta-1 fusion proteins |
US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
JP2003152145A (ja) * | 2001-08-31 | 2003-05-23 | Sumitomo Electric Ind Ltd | 半導体放熱用基板とその製造方法及びパッケージ |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7399613B2 (en) * | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7795210B2 (en) * | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7179617B2 (en) * | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7473680B2 (en) | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
CA2471363C (en) * | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AU2002364587A1 (en) * | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
MXPA04012496A (es) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
SI21258A (sl) * | 2002-07-17 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol |
US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
AU2003273297A1 (en) * | 2002-09-09 | 2004-03-29 | Kenneth S. Warren Institute, Inc. | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
CN1703421B (zh) * | 2002-09-20 | 2010-06-23 | 法玛西亚公司 | 降低peg化蛋白的聚集体水平的方法 |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
CA2519092C (en) * | 2003-03-14 | 2014-08-05 | Neose Technologies, Inc. | Branched water-soluble polymers and their conjugates |
PL1615945T3 (pl) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
WO2007022512A2 (en) * | 2005-08-19 | 2007-02-22 | Neose Technologies, Inc. | Glycopegylated factor vii and factor viia |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
US7691603B2 (en) * | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
BRPI0410164A (pt) * | 2003-05-09 | 2006-05-16 | Neose Technologies Inc | composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano |
US7919118B2 (en) | 2003-05-12 | 2011-04-05 | Affymax, Inc. | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
MXPA05012313A (es) * | 2003-05-12 | 2006-04-18 | Affymax Inc | Peptidos que se unen al receptor de eritropoyetina. |
KR101163683B1 (ko) | 2003-05-12 | 2012-07-10 | 아피맥스, 인크. | 에리스로포이에틴 수용체에 결합하는 신규의 펩티드 |
DE602004028725D1 (de) * | 2003-05-12 | 2010-09-30 | Affymax Inc | Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen |
AU2004244920B2 (en) | 2003-06-10 | 2009-07-23 | Lg Chem, Ltd. | Stable, aqueous solution of human erythropoietin, not containing serum albumin |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US8633157B2 (en) * | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) * | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
KR20060120141A (ko) * | 2003-11-24 | 2006-11-24 | 네오스 테크놀로지스, 인크. | 글리코페질화 에리트로포이에틴 |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
BRPI0417342A (pt) * | 2003-12-03 | 2007-04-17 | Neose Technologies Inc | fator estimulante de colÈnia de granulócitos glicopeguilado |
US20080318850A1 (en) * | 2003-12-03 | 2008-12-25 | Neose Technologies, Inc. | Glycopegylated Factor Ix |
SI1696947T1 (sl) | 2003-12-19 | 2014-05-30 | F. Hoffmann-La Roche Ag | Uporaba eritropoetina pri zdravljenju motenj porazdelitve železa pri kroničnih vnetnih črevesnih boleznih |
KR101439880B1 (ko) * | 2004-01-08 | 2014-09-12 | 라티오팜 게엠베하 | 펩티드의 오-결합형 글리코실화 |
AU2005211385B2 (en) * | 2004-02-02 | 2008-12-11 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
DE102004011663B4 (de) * | 2004-03-10 | 2006-04-27 | Bioceuticals Arzneimittel Ag | Erythropoietin-Flüssigformulierung |
US20050282751A1 (en) * | 2004-03-19 | 2005-12-22 | Ajinomoto Co., Inc. | Therapeutic agent for renal anemia |
EP1726303A4 (en) * | 2004-03-19 | 2011-03-02 | Ajinomoto Kk | THERAPEUTIC AGENT AGAINST KIDNEY ANEMIA |
KR20070015549A (ko) * | 2004-03-26 | 2007-02-05 | 얀센 파마슈티카 엔.브이. | 에리트로포이에틴의 병용 용량요법 |
AR049580A1 (es) * | 2004-07-07 | 2006-08-16 | Lundbeck & Co As H | Epo carbamilada y metodo para su produccion |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
US20090292110A1 (en) * | 2004-07-23 | 2009-11-26 | Defrees Shawn | Enzymatic modification of glycopeptides |
US7772182B2 (en) * | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
US20060029551A1 (en) * | 2004-08-05 | 2006-02-09 | Kui Liu | Stable particle formulations of erythropoietin receptor agonists |
EP1799249A2 (en) * | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
WO2006050247A2 (en) * | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
JP2006137678A (ja) * | 2004-11-10 | 2006-06-01 | Shionogi & Co Ltd | インターロイキン−2組成物 |
WO2006060148A2 (en) * | 2004-11-11 | 2006-06-08 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
EP1838332A1 (en) * | 2005-01-06 | 2007-10-03 | Neose Technologies, Inc. | Glycoconjugation using saccharyl fragments |
NZ556436A (en) | 2005-01-10 | 2010-11-26 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
CA2595676A1 (en) * | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
WO2006105426A2 (en) * | 2005-03-30 | 2006-10-05 | Neose Technologies, Inc. | Manufacturing process for the production of peptides grown in insect cell lines |
EP2386571B1 (en) * | 2005-04-08 | 2016-06-01 | ratiopharm GmbH | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US20070037886A1 (en) * | 2005-04-26 | 2007-02-15 | Ajinomoto Co., Inc. | Bone marrow erythroid progenitor cell(s) differentiation inducer |
JP5216580B2 (ja) * | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | グリコペグ化第ix因子 |
US20110003744A1 (en) * | 2005-05-25 | 2011-01-06 | Novo Nordisk A/S | Glycopegylated Erythropoietin Formulations |
WO2006127910A2 (en) * | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7550433B2 (en) * | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7919461B2 (en) | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
AU2006295340B2 (en) | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
US20090048440A1 (en) * | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
CA3045808C (en) | 2005-11-23 | 2022-08-16 | Acceleron Pharma, Inc. | Activin-actriia antagonists and uses for promoting bone growth |
CN101015684B (zh) * | 2006-02-10 | 2011-08-24 | 华北制药集团新药研究开发有限责任公司 | 一种重组人红细胞生成素溶液制剂 |
US8546329B2 (en) * | 2006-03-22 | 2013-10-01 | Chugai Seiyaku Kabushiki Kaisha | Erythropoietin solution preparation |
ES2516694T3 (es) * | 2006-07-21 | 2014-10-31 | Ratiopharm Gmbh | Glicosilación de péptidos a través de secuencias de glicosilación con unión en O |
DK2054074T3 (da) * | 2006-08-04 | 2014-11-03 | Prolong Pharmaceuticals Llc | Modificeret erythropoietin |
WO2008057683A2 (en) | 2006-10-03 | 2008-05-15 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
LT2068907T (lt) * | 2006-10-04 | 2018-01-10 | Novo Nordisk A/S | Glicerolio sujungti pegilinti sacharidai ir glikopeptidai |
WO2008073620A2 (en) * | 2006-11-02 | 2008-06-19 | Neose Technologies, Inc. | Manufacturing process for the production of polypeptides expressed in insect cell-lines |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
TW201907946A (zh) | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
BRPI0809670A8 (pt) | 2007-04-03 | 2018-12-18 | Biogenerix Ag | métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral. |
US20090053167A1 (en) * | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
US20080286341A1 (en) * | 2007-05-16 | 2008-11-20 | Sven-Borje Andersson | Buffered coated nicotine containing products |
US20110177029A1 (en) * | 2007-06-04 | 2011-07-21 | Novo Nordisk A/S | O-linked glycosylation using n-acetylglucosaminyl transferases |
CN101778859B (zh) | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | 改良的用于生产核苷酸糖的方法 |
AU2008269086B2 (en) * | 2007-06-25 | 2014-06-12 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
US7968811B2 (en) * | 2007-06-29 | 2011-06-28 | Harley-Davidson Motor Company Group, Inc. | Integrated ignition and key switch |
CL2008002053A1 (es) * | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
AR067536A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
EP2197919B1 (en) | 2007-08-27 | 2014-04-09 | ratiopharm GmbH | Liquid formulation of g-csf conjugate |
US8207112B2 (en) * | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
CN101456911A (zh) * | 2007-12-12 | 2009-06-17 | 江苏豪森药业股份有限公司 | ***模拟肽衍生物及其可药用盐和其制备方法与用途 |
US20100286067A1 (en) * | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
CN103497246B (zh) | 2008-02-27 | 2016-08-10 | 诺沃—诺迪斯克有限公司 | 缀合的因子viii分子 |
HRP20230761T1 (hr) | 2008-08-14 | 2023-10-13 | Acceleron Pharma Inc. | Gdf zamke |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
WO2010034442A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Purification of erythropoietin |
AU2010258931B2 (en) | 2009-06-08 | 2015-04-23 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
US8293881B2 (en) | 2009-06-12 | 2012-10-23 | Acceleron Pharma Inc. | Isolated nucleic acid encoding a truncated ActRIIB fusion protein |
SG177319A1 (en) | 2009-06-24 | 2012-02-28 | Hoffmann La Roche | Characterization of re-useable chromatography equipment |
BRPI0902481B8 (pt) * | 2009-07-31 | 2021-05-25 | Soc Beneficente De Senhoras Hospital Sirio Libanes | composição farmacêutica compreendendo hemopressina e seu uso. |
IL287990B (en) * | 2009-08-13 | 2022-07-01 | Acceleron Pharma Inc | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
US20120264688A1 (en) * | 2009-09-23 | 2012-10-18 | Walter Hinderer | Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same |
ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
WO2012084828A1 (en) | 2010-12-21 | 2012-06-28 | F. Hoffmann-La Roche Ag | Chromatography equipment characterization |
AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
CN102816227A (zh) * | 2012-08-30 | 2012-12-12 | 深圳赛保尔生物药业有限公司 | 回收***的方法 |
WO2014071158A1 (en) | 2012-11-02 | 2014-05-08 | Celgene Corporation | Activin-actrii antagonists and uses for treating bone and other disorders |
CU20140003A7 (es) | 2014-01-08 | 2015-08-27 | Ct De Inmunología Molecular Biofarmacuba | Conjugado que comprende eritropoyetina y una estructura polimérica ramificada |
ES2843685T3 (es) | 2014-03-29 | 2021-07-20 | Intas Pharmaceuticals Ltd | Composición farmacéutica líquida de eritropoyetina conjugada |
CA2951926C (en) | 2014-06-13 | 2023-01-10 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
WO2018184692A1 (en) * | 2017-04-07 | 2018-10-11 | Ares Trading S.A. | Liquid pharmaceutical composition |
SG11202005952TA (en) * | 2017-12-29 | 2020-07-29 | Hoffmann La Roche | Process for providing pegylated protein composition |
CN111558046A (zh) * | 2020-05-27 | 2020-08-21 | 华润昂德生物药业有限公司 | 海藻糖在制备重组人促红素液体制剂中的应用及重组人促红素液体制剂、制备方法和应用 |
TWI740635B (zh) * | 2020-09-09 | 2021-09-21 | 財團法人工業技術研究院 | 聚偏氟乙烯薄膜組成物及聚偏氟乙烯隔離膜 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US115833A (en) * | 1871-06-13 | Improvement in grain-driers | ||
US147431A (en) * | 1874-02-10 | Improvement in game boards | ||
JPS6197229A (ja) | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
US4732889A (en) * | 1985-02-06 | 1988-03-22 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis |
DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
DE3734923C1 (de) | 1987-10-15 | 1989-01-26 | Biotest Pharma Gmbh | Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt |
DE4014654A1 (de) | 1990-05-08 | 1991-11-14 | Behringwerke Ag | Galenische waessrige formulierungen von erythropoietin und ihre verwendung |
EP0503050A4 (en) * | 1990-09-28 | 1994-07-06 | Ortho Pharma Corp | Hybrid growth factors |
US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
DE4135542A1 (de) | 1991-10-28 | 1993-04-29 | Boehringer Mannheim Gmbh | Lagerfaehige proteinloesungen |
US5460944A (en) | 1991-10-28 | 1995-10-24 | Boehringer Mannheim Gmbh | Storable protein solution |
US5716644A (en) * | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
US5354934A (en) † | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
CN1057534C (zh) * | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | ***类似物 |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
IL128229A0 (en) † | 1996-08-02 | 1999-11-30 | Ortho Mcneil Pharm Inc | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
US5919656A (en) | 1996-11-15 | 1999-07-06 | Amgen Canada Inc. | Genes encoding telomerase protein 1 |
EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
DE19734293A1 (de) | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
AR020848A1 (es) | 1998-10-23 | 2002-05-29 | Amgen Inc | Metodos y composiciones para la prevencion y el tratamiento de anemia |
UY25790A1 (es) | 1998-11-06 | 2000-08-21 | Bio Sidus S A | Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion. |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
ATE401908T1 (de) | 1999-04-09 | 2008-08-15 | Ortho Mcneil Pharm Inc | Pharmazeutische zusammensetzungen von erythropoietin |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
CZ299516B6 (cs) † | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
CN101091792A (zh) | 1999-07-22 | 2007-12-26 | 阿温蒂斯药物公司 | 多剂量红细胞生成素制剂 |
ATE389414T1 (de) † | 1999-09-08 | 2008-04-15 | Chugai Pharmaceutical Co Ltd | Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben |
AU2001236005A1 (en) | 2000-02-29 | 2001-09-12 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilized over long time |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
WO2001087329A1 (en) * | 2000-05-15 | 2001-11-22 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivate |
WO2002011753A1 (fr) † | 2000-08-04 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | Preparations proteiniques a injecter |
MXPA03005406A (es) * | 2000-12-20 | 2003-09-25 | Hoffmann La Roche | Conjugados de eritropoyetina. |
US20030104996A1 (en) | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
US6818613B2 (en) | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
-
2001
- 2001-05-08 WO PCT/EP2001/005187 patent/WO2001087329A1/en not_active Application Discontinuation
- 2001-05-08 DK DK01943331.7T patent/DK1311285T4/en active
- 2001-05-08 PL PL361341A patent/PL219131B1/pl unknown
- 2001-05-08 KR KR1020077003371A patent/KR20070032815A/ko not_active Application Discontinuation
- 2001-05-08 DE DE60109625.8T patent/DE60109625T3/de not_active Expired - Lifetime
- 2001-05-08 CN CNB018095607A patent/CN1309416C/zh not_active Expired - Lifetime
- 2001-05-08 AU AU65934/01A patent/AU784091B2/en active Active
- 2001-05-08 CA CA2408685A patent/CA2408685C/en not_active Expired - Lifetime
- 2001-05-08 KR KR1020057023568A patent/KR20050121762A/ko not_active Application Discontinuation
- 2001-05-08 RU RU2002133236/15A patent/RU2281116C2/ru active
- 2001-05-08 PT PT01943331T patent/PT1311285E/pt unknown
- 2001-05-08 IL IL15265901A patent/IL152659A0/xx unknown
- 2001-05-08 KR KR1020027015429A patent/KR100758044B1/ko active IP Right Grant
- 2001-05-08 ES ES01943331.7T patent/ES2237574T5/es not_active Expired - Lifetime
- 2001-05-08 AT AT01943331T patent/ATE291436T2/de active
- 2001-05-08 HU HU0302114A patent/HU230874B1/hu unknown
- 2001-05-08 BR BRPI0110914A patent/BRPI0110914B8/pt not_active IP Right Cessation
- 2001-05-08 EP EP05000984A patent/EP1525889A1/en not_active Withdrawn
- 2001-05-08 RS YUP-835/02A patent/RS51292B/sr unknown
- 2001-05-08 ME MEP-907/08A patent/MEP90708A/xx unknown
- 2001-05-08 SI SI200130331T patent/SI1311285T1/xx unknown
- 2001-05-08 JP JP2001583796A patent/JP3967594B2/ja not_active Expired - Lifetime
- 2001-05-08 MX MXPA02011303A patent/MXPA02011303A/es active IP Right Grant
- 2001-05-08 EP EP01943331.7A patent/EP1311285B2/en not_active Expired - Lifetime
- 2001-05-08 CZ CZ2002-4005A patent/CZ304855B6/cs not_active IP Right Cessation
- 2001-05-08 NZ NZ522030A patent/NZ522030A/en not_active IP Right Cessation
- 2001-05-09 JO JOP/2001/0065A patent/JO3404B1/ar active
- 2001-05-11 AR ARP010102248A patent/AR035034A1/es not_active Application Discontinuation
- 2001-05-11 PE PE2001000421A patent/PE20020050A1/es active IP Right Grant
- 2001-05-11 MY MYPI20012197A patent/MY128654A/en unknown
- 2001-05-11 US US09/853,731 patent/US7169754B2/en not_active Expired - Lifetime
- 2001-05-14 UY UY26704A patent/UY26704A1/es not_active IP Right Cessation
- 2001-05-14 TW TW090111453A patent/TWI288643B/zh not_active IP Right Cessation
- 2001-05-14 TW TW094134688A patent/TWI288644B/zh not_active IP Right Cessation
-
2002
- 2002-10-21 ZA ZA200208500A patent/ZA200208500B/en unknown
- 2002-11-05 IL IL152659A patent/IL152659A/en active IP Right Grant
- 2002-11-07 HR HR20020880A patent/HRP20020880B1/xx not_active IP Right Cessation
- 2002-11-13 MA MA26907A patent/MA26901A1/fr unknown
- 2002-11-14 NO NO20025450A patent/NO330934B1/no not_active IP Right Cessation
- 2002-11-20 EC EC2002004352A patent/ECSP024352A/es unknown
-
2003
- 2003-12-11 HK HK03109033A patent/HK1056683A1/xx unknown
-
2004
- 2004-02-17 US US10/780,297 patent/US7202208B2/en not_active Expired - Lifetime
-
2010
- 2010-12-21 EC EC2010004352A patent/ECSP10004352A/es unknown
-
2013
- 2013-10-04 AR ARP130103618A patent/AR092919A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU83502A (sh) | Nova farmaceutska smeša | |
MY106315A (en) | Pharmaceutical agents | |
IL145429A0 (en) | N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same | |
MXPA04000920A (es) | Derivados de aminoisoxazol activos como inhibidores de la cinasa. | |
WO2001098290A3 (en) | Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
EA200100524A1 (ru) | Амиды антраниловой кислоты и их применение в качестве лекарственных средств | |
HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
BG101118A (en) | Therapeutical compounds | |
FR06C0032I2 (fr) | Formulations proteiniques | |
MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
CA2284551A1 (en) | New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders | |
IT1276162B1 (it) | Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche | |
MX9704034A (es) | Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso. | |
MXPA02011533A (es) | Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona. | |
MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine | |
HK1050203A1 (en) | Novel fusidic acid derivatives. | |
IL160160A0 (en) | SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS | |
IT1307866B1 (it) | Composizioni farmaceutiche contenenti inibitori dell'ormone dellacrescita o loro frammenti biologicamente attivi per il trattamento |